XC 7
Alternative Names: XC-7Latest Information Update: 28 Jan 2024
Price :
$50 *
At a glance
- Originator NP Therapeutics
- Class Antivirals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in Russia (PO, Capsule)
- 09 Apr 2021 NP Therapeutics completes phase I trial in COVID-2019 infections (In Volunteers) in Russia (PO, Capsule)(NCT04679493)
- 29 Dec 2020 NP Therapeutics plans a phase I trial in COVID-2019 infections (In Volunteers) in Russia (PO, Capsule) (NCT04679493)